- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | RenovoRx Says FDA Grants Orphan Drug Status For Oxaliplatin To Treat Pancreatic Cancer | 1 | RTTNews | ||
| 28.05. | RenovoRx, Inc.: RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer | 449 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing... ► Artikel lesen | |
| 26.05. | RenovoRx, Inc.: RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 19.05. | RenovoRx, Inc.: RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th | 1 | GlobeNewswire (USA) | ||
| 15.05. | RenovoRx, Inc. - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 14.05. | RenovoRx, Inc. (RNXT) Reports Q1 Loss, Tops Revenue Estimates | 1 | Zacks | ||
| 14.05. | RenovoRx Reports Q1 2026 Results: Full Earnings Call Transcript | 1 | Benzinga.com | ||
| 14.05. | RenovoRx GAAP EPS of -$0.09 misses by $0.01, revenue of $0.56M beats by $0.1M | 2 | Seeking Alpha | ||
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| 14.05. | RenovoRx, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.05. | RenovoRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.04. | RenovoRx, Inc.: Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx's TAMP Therapy Platform Presented at 2026 SIR Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 08.04. | RenovoRx, Inc.: RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath Device for Targeted, Local Drug-Delivery via the Vasa Vasorum | 1 | GlobeNewswire (USA) | ||
| 01.04. | RenovoRx, Inc.: RenovoRx Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026 | 1 | GlobeNewswire (USA) | ||
| 31.03. | RenovoRx, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.03. | RenovoRx, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | RenovoRx GAAP EPS of -$0.32 in-line, revenue of $1.12M misses by $0.18M | 1 | Seeking Alpha | ||
| 30.03. | RenovoRx, Inc.: RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update | 570 | GlobeNewswire (Europe) | RenovoCath- Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated... ► Artikel lesen | |
| 27.03. | RenovoRx ernennt Dr. Ramtin Agah zum Executive Chairman und passt Vergütung an | 3 | Investing.com Deutsch | ||
| 26.03. | RenovoRx surpasses 100 patients in Phase III pancreatic trial | 7 | Investing.com |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| BIOGEN | 171,56 | +1,19 % | Biogen's Salanersen Wins FDA Breakthrough Therapy Designation For Spinal Muscular Atrophy Treatment | WESTON (dpa-AFX) - Thursday, Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has granted salanersen Breakthrough Therapy Designation for the treatment of spinal muscular... ► Artikel lesen | |
| ILLUMINA | 139,80 | -0,70 % | ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge? | ||
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results | Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-503... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,650 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TEMPUS AI | 40,195 | -0,22 % | Tempus AI gründet Open-Source-Konsortium für digitale Pathologie | ||
| ATAIBECKLEY | 3,400 | -0,58 % | AtaiBeckley Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 3,315 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| TWIST BIOSCIENCE | 60,88 | +1,43 % | LenioBio GmbH: LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery | LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,150 | -0,69 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOXCEL THERAPEUTICS | 0,980 | +2,08 % | BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia... ► Artikel lesen | |
| PDS BIOTECHNOLOGY | 0,906 | +1,12 % | PDS Biotechnology Corp - 8-K, Current Report | ||
| MEREO BIOPHARMA | 0,266 | +0,76 % | Mereo BioPharma Group plc: Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates | LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial... ► Artikel lesen |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,002 (+0,26 %) liegt der Kurs bei 0,874 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.